Articles

Highlights of the 21st annual European Neuroendocrine Tumour Society (ENETS) Conference

BJMO - volume 18, issue 4, june

W. Lybaert MD, T. Vandamme MD, PhD, L. Mariën MSc, O. Islam MD, S. Chhajlani MD, C. De Weerdt MSc, I. Nietvelt MSc, M. Ulenaers MD, V. Casneuf MD, M. Maly MD, K. Geboes MD, PhD, D. Van Genechten , H. Leupe MD, C.M. Deroose MD, PhD

SUMMARY

During the ENETS Conference, the NETTER-2 trial was again in the spotlight and is shifting [177Lu]Lu-DOTATATE PRRT to the first-line treatment setting of patients with advanced, well-differentiated grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours (NET). Nuclear medicine treatment for NET is now intensively focusing on alpha-emitting peptide receptor radionuclide therapy (PRRT). Adding immunotherapy to angiogenesis inhibition for NET is again a disappointing story, and all eyes are now set on the CAR T-cell technology to stimulate anti-tumour immune responses. Delta-like ligand 3 is an inhibitory Notch ligand selectively and highly expressed on the cell surface of small cell lung cancer and neuroendocrine carcinoma, and appears to be a promising target for bispecific T-cell engager therapy. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.

(BELG J MED ONCOL 2024;18(4):164–75)

Read more

Highlights of the 2018 Annual European Neuroendocrine Tumor Society (ENETS) Congress

BJMO - volume 12, issue 5, september 2018

W. Lybaert MD, T. Vandamme MD, PhD, G. Boons , T. Rondou , M. Twickler , I. Dero MD, F. van Fraeyenhove MD, L. De Backer , D. Van Genechten , M. Peeters MD, PhD

March 7-9, 2018, Barcelona, Spain.

(BELG J MED ONCOL 2018:12(5):252–262)

Read more